Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long [Yahoo! Finance]
Longeveron Inc. - Class A Common stock (LGVN)
Company Research
Source: Yahoo! Finance
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The US$23m market-cap company announced a latest loss of US$16m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on Longeveron's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company. View our latest analysis for Longeveron Consensus from 4 of the American Biotechs analysts is that Longeveron is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$750k in 202
Read more
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - Class A Common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s DiseaseGlobeNewswire
- Longeveron® to Present at the 37th Annual Roth ConferenceGlobeNewswire
- Longeveron Inc. (NASDAQ: LGVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
LGVN
Earnings
- 11/12/24 - Beat
LGVN
Analyst Actions
- 3/3/25 - HC Wainwright
LGVN
Sec Filings
- 3/6/25 - Form 4
- 2/28/25 - Form 8-K
- 2/28/25 - Form 10-K
- LGVN's page on the SEC website